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Abstract. Head and neck squamous cell carcinoma (HNSCC) 
poses a significant challenge clinically where one of the 
mechanisms responsible for the invasion into facial bones 
occurs via the activation of osteoclasts. Copper has been 
demonstrated to play a key role in skeletal remodeling. 
However, the role of copper in cancer-associated bone 
destruction is thus far unknown. Lysyl oxidase (LOX) is a 
copper-dependent enzyme that promotes osteoclastogenesis. 
In the present study, we investigated the effects of copper 
on HNSCC with bone invasion by the copper chelator, 
ammonium tetrathiomolybdate (TM) in vitro and in vivo. 
We demonstrate that TM blocks the proliferation of HNSCC 
cells, inhibits LOX activation and decreases the expression of 
the receptor activator of nuclear factor-κB ligand (RANKL) 
in osteoblasts and osteocytes, subsequently suppressing bone 
destruction. These findings suggest that copper is a potential 
target for the treatment of HNSCCs associated with bone 
destruction.
Introduction
Head and neck squamous cell carcinoma (HNSCC) frequently 
invades the facial bones, and this invasion is a prognostic factor 
for poor clinical outcomes (1,2). Bone resection is a treatment 
that often leads to the post-operative disruption of speech and 
swallowing functions, and thus poses a significant challenge 
to the quality of life of patients with HNSCC presenting with 
facial bone invasion. Cancer cells have been demonstrated to 
secrete significant amounts of growth factors, which promotes 
osteoclastogenesis (3). Therefore, it is critical that novel 
approaches should be evaluated for the treatment of bone 
destruction in advanced HNSCC. Copper is known as a key 
factor for cellular metabolism, neuronal transmission and bone 
remodeling (4,5). Copper metabolic disorder induces Wilson's 
disease, a rare inherited disorder that causes copper to accu-
mulate in the liver, brain and other vital organs (6). The copper 
chelator, ammonium tetrathiomolybdate (TM), is used for the 
treatment of copper metabolic disorder and Wilson's disease. 
In addition, recent research has revealed that copper chelators 
exert an antitumor effect against several cancer types, such as 
breast cancer with lung metastases and head and neck cancer 
(7,8).
Copper is a factor that binds to selected enzymes and 
functions to increase their activation. For example, Lysyl 
oxidase (LOX) is the prototypical member of copper-
dependent enzymes whose documented function is to oxidize 
primary amine substrates to reactive aldehydes (9). The most 
well-characterized role of LOX is in the remodeling of the 
extracellular matrix (ECM) through the oxidative deamination 
of peptidyl lysine residues in collagens and elastin to facilitate 
covalent cross-linking (10). It has also been reported that LOX 
is essential for bone remodeling via the regulation of receptor 
activator of nuclear factor-κB ligand (RANKL) expression 
on bone marrow stromal cells (11,12). Cancer cells release 
significant amounts of LOX (13). This copper-dependent LOX 
activation may promote bone resorption; however, the role of 
copper in bone resorption in HNSCC remains unclear and thus 
requires clarification.
In the present study, we thus aimed to determine the role 
of copper in bone resorption in HNSCC. To the best of our 
knowledge, we are the first to provide evidence that the copper 
chelator, TM, exerts an anti-bone destruction effect against 
cancer-induced bone resorption and that TM enhances the 
antitumor effect of a clinically validated anticancer agent on 
HNSCC associated with bone invasion.
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Materials and methods
Cell lines and culture conditions. The human HNSCC cell 
lines, HSC-2 (#JCRB0622), HSC-3 (#JCRB0523) and SAS 
(#JCRB0260), were obtained from the Human Science Research 
Resources Bank (Osaka, Japan). All cell lines were cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS). Primary 
fibroblasts were obtained from Cosmo Bio (#SCR2620, Tokyo, 
Japan).
Primary osteoblasts, osteocytes, bone marrow cells 
(obtained as described below), and fibroblasts were cultured in 
alpha-modification of minimum essential medium (α-MEM). 
T cells (obtained as described below) were cultured in RPMI-1640 
medium supplemented with 10% FBS, 1% penicillin-strepto-
mycin, 10 mM 2-mercaptoethanol (Sigma, St. Louis, MO, USA) 
and Pyruvic acid (Wako, Osaka Japan). All of the above-cited 
cell lines were characterized by genotyping at cell banks. All 
cell lines were cultured in an atmosphere of 10% CO2 at 37˚C.
Osteoclastogenesis assay. Bone marrow cells were obtained 
from the femurs and tibiae of 4-week-old male C57BL/6 mice 
(n=2), purchased from Charles River Laboratories (Yokoyama, 
Japan). Under anesthesia with 0.4 mg/kg of medetomidine, 
4.0 mg/kg of midazolam and 5.0 mg/kg of butorphanol, the 
mice were sacrificed by cervical dislocation. After the leg was 
cut, muscle and connective tissue was removed from the tibiae 
and femurs. Both ends of the femur and tibiae were then clipped 
with a scissors. A 5 cc syringe was filled using a 27 gauge 
needle with PBS, and a needle was inserted into one end and 
the bone marrow was flushed out the other end. The flushed 
bone marrow cells wre corrected in a 50 cc tube. The bone 
marrow cells were washed twice by centrifugation (125 x g, 
10 min) in 4˚C PBS. The cells were the nincubated in α-MEM 
in 10 cm culture dishes in the presence of macrophage colony-
stimulating factor (M-CSF) (10 ng/ml) for 24 h. Non-adherent 
cells were transferred to 24-well plates (2x106 cells/well). The 
cells were treated with vitamin D3, 1,25-Dihydroxy (10-8 M) 
and TM (0.1, 1, 2.5 and 5 µM) for 9 days.
Purification of osteoclast progenitors. Bone marrow cells 
were washed twice by centrifugation (125 x g, 10 min) in 
20 ml of 4˚C sterile phosphate-buffered saline (PBS) supple-
mented with 0.5% bovine serum albumin. The cell pellet was 
resuspended, and the cells were magnetically labeled by the 
addition of anti-CD11b microbeads (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany). The cells were then incubated 
for 30 min on ice and then washed by centrifugation (125 x g, 
10 min) with a volume of 4˚C buffer that was 10-fold that of the 
labeling volume and resuspended. CD11b+ cells were depleted 
using an MD depletion column (Miltenyi Biotec GmbH). A 
total of 1x105 murine CD11b+ bone marrow cells/well were 
plated in a 24-well plate. The cells were treated with RANKL 
(50 ng/ml) and M-CSF (30 ng/ml) and the desired amount 
of TM (0.1, 1, 2.5 and 5 µM) for 9 days. Following 9 days 
of incubation, the cells were fixed and stained for tartrate-
resistant acid phosphatase activity using the acid phosphatase, 
leukocyte (TRAP) kit (#A386A, Merck KGaA, Darmstadt, 
Germany), and the number of TRAP-positive multinucleate 
cells (i.e., a nuclear number >3) in each well was then counted.
Cell proliferation assay. The HSC-2, HSC-3 and SAS cells 
were each plated in 6-well plates at a density of 5x103 cells 
per well and treated with the TM (1, 5 µM) or with an equiva-
lent volume of the diluent (DMSO) as a control for 5 days. 
Osteoblasts, osteocytes and fibroblasts were each plated in 
6-well plates at a density of 1x104 cells per well and treated 
with TM (1, 5 µM) for 48 h. CD4+ T cells were isolated by 
the magnetic sorting system. The cells from the homozenized 
spleens of two C57BL/6J mice were incubated with CD4 
antibody-conjugated microbeads (eBioscience, San Diego, CA, 
USA) and sorted with MD depletion column (Miltenyi Biotec). 
The cells were stimulated with anti-CD3 monoclonal antibody 
(Cat. no. 16-0031, 5 µg/ml), CD28 antibody (Cat. no. 16-0281, 
2 µg/ml) (Affymetrix, Santa Clara, CA, USA) and TM 
(1, 5 µM) for 48 h. The cell number was then counted with 
trypan blue assay. Osteoblasts were obtained following 
the method of Teramachi et al (14). After flushing the bone 
marrow from the tibiae of 3 C57BL/6J mice, the tibiae were 
cultured in αMEM for 7-10 days in 60-mm dishes until the 
cells growing out of the bones formed a confluent monolayer. 
The original bone was removed, and the cells grown out of the 
the bone were treated with 0.25% trypsin and 0.05% EDTA 
for 10 min at 37˚C. These cells were used as primary osteoblas 
without further passage. Osteocytes were obtained following 
the method of Shah et al (15). After flushing the bone marrow 
from the tibiae of the 2 C57BL/6J mice, the bones were 
dissected into 1-2-mm sized sections. The bone sections were 
then incubated for 25 min in collagenase (300 units/ml) and 
0.25% EDTA (5 mM) and the collagenase was removed and 
discarded. These processes were repeated 8 times. The cells 
from the bone sections were cultured as osteocytes without 
further passage. These cells were classified as osteocytes by 
measuring dentin matrix acidic phosphoprotein 1 (DMP-1) 
expression by western blot analysis (data not shown).
Copper concentration measurement assay. The copper 
concentrations in the culture medium and serum, collected 
from the tail vein of the mice inoculated with the cancer cells 
at the time of sacrifice were measured using the Metallo Assay 
Copper Assay kit (Funakoshi, Tokyo, Japan). The samples, 
buffer and chelate color solution were mixed and incubated 
for 10 min at room temperature. Subsequently, the absorbance 
was read at a 580 nm wavelength using a microplate reader 
(SH-1000, Hitachi, Tokyo, Japan).
LOX activity assay. The HSC-2 and SAS cells were cultured 
in DMEM with increased copper ion (10 µM) in the presence 
or absence of TM for 24 h. Conditioned medium and serum 
collected from the mice inoculated with the cancer cells were 
tested using a LOX activity kit (Cat. no. ab112139, Abcam, 
Cambridge, MA, USA). The samples and LOX reaction 
mix solution were mixed and incubated for 30 min at room 
temperature. Subsequently, the fluorescence increase was 
measured on a microplate reader (Gemini EM microplate 
reader, Molecular Devices, Sunnyvale, CA, USA) at excitation 
and emission wavelengths of 550 and 600 nm. These condi-
tioned media were used in the following experiment.
Western blot analysis. The osteocytes and osteoblasts were 
cultured in the above-mentioned conditioned media (30%) 
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for 24 h. The cell culture conditioned media (25 µl) were 
mixed with 4X Laemmli sample buffer (Bio-Rad, Hercules, 
CA, USA) and boiled at 95˚C for 5 min. The samples were 
electrophoresed in 4-12% SDS-PAGE gels and the proteins 
were transferred onto membranes (Immobilon-P; Millipore, 
Bedford, MA, USA). The membranes were incubated with 
primary and secondary antibodies according to the ECL chemi-
luminescence protocol (RPN2109; Amersham Biosciences, 
Buckinghamshire, UK) to detect secondary antibody binding. 
Antibodies against RANKL (Cat. no. sc-377079, 1:1,000, 
Santa Cruz Biotechnology (Dallas, TX, USA) was used as a 
primary antibody and HRP-conjugated anti-mouse antibody 
(Cat. no. 7076, 1:2,000, Cell Signaling Technology, Danvers, 
MA, USA) was used as the secondary antibody.
Immunohistochemical analysis. The tibial bone and soft tumor 
was fixed in 10% formalin, decalcified and then embedded in 
paraffin. Serial sections were then prepared (3-µm-thick). For 
immunohistochemical analysis, the specimens were incubated 
with antibody (CD-31, 1:50, Cat. no. ab28364, Abcam), (Ki67, 
1:400, Cat. no. 9129, Cell Signaling Technology), (EGFR, 1:50, 
Cat. no. 4267, Cell Signaling Technology), (p-EGFR, 1:200, 
Cat. no. 3777, Cell Signaling Technology), (RANKL, 1:100, 
Cat. no. sc-377079, Santa Cruz Biotechnology) overnight at 
4˚C, followed by 3 washes with TBS. The slides were then 
treated with a streptoavidin-biotin complex [EnVision System 
labelled polymer, horseradish peroxidase (HRP); Dako, 
Carpinteria, CA, USA] for 60 min at a dilution of 1:100. The 
immunoreaction was visualized by using a DAB substrate-
chromogen solution (Dako Cytomation Liquid DAB Substrate 
Chromogen System; Dako). The cells were counted using a 
microscope and evaluated.
Animal experiments. Mouse models of bone invasion by human 
oral squamous cell carcinoma were established in 5-week-old 
female BALB/c nude mice (each group, n=5; total, n=20, mean 
body weight, 19.5 g; Charles River Laboratories) by the inocu-
lation of 1x105 HSC-2 cells into the bone marrow space of the 
left tibial metaphysis. At 7 days after tumor cell inoculation, the 
mice were divided into 4 groups (control, cetuximab-treated, 
TM-treated, and TM- and cetuximab-treated). The cetuximab 
group was treated with an intraperitoneal injection of 100 µl of 
Figure 1. Effects of ammonium tetrathiomolybdate (TM) on the proliferation of HNSCC and bone microenvironment cells in vitro (A) HSC2 cells, (B) HSC3 
cells, (C) SAS cells, (E) osteoblasts, (F) osteocytes, (G) fibroblasts, and (H) T cells were plated in triplicate and treated with 0, 1, or 5 µM TM for 48 h. Error 
bars indicate the means ± SD; *P<0.05 vs. control. (D) Copper concentration in culture medium from HNSCC cells treated with TM (5 µM) for 48 h. Error bars 
indicate the means ± SD; *P<0.05 vs. untreated cells.
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a solution containing cetuximab (1 mg/kg) in PBS or PBS alone 
twice a week for 5 weeks. The TM group was orally admin-
istered a 100 µl solution containing TM (1 mg) in distilled 
deionized water (DDW) or DDW alone 5 times a week for 
5 weeks. Under anesthesia with 0.4 mg/kg of medetomidine, 
4.0 mg/kg of midazolam and 5.0 mg/kg of butorphanol, the 
hind limb long bones of the nude mice that had been injected 
with the cancer cells were excised, fixed in 10% neutral-
buffered formalin. Osteolytic bone destruction was assessed on 
radiographs. The bones were placed against films (22x27 cm; 
Fuji industrial film FR: Fuji Photo Film Co. Ltd., Tokyo, Japan), 
and exposed to soft X-rays at 35 kV for 15 sec by the use of a 
Sofron apparatus (Sofron, Tokyo, Japan). The radiolucent bone 
lesions were observed microscopically (IX81, Olympus, Tokyo, 
Japan), and the areas were quantified with Lumina Vision/OL 
(Mitani, Tokyo, Japan). A micro-CT image was obtained with 
SKYSCAN (Bruker Japan, Kanagawa, Japan). Subsequently, 
the bone was decalcified and embedded in paraffin. Serial 
sections (3 µm-thick) were cut cross-sectionally, and the 
sections were stained with TRAP stain.
Human oral squamous cell carcinoma xenografts were 
established in 5-week-old male BALB/c nude mice (each 
group, n=5; total, n=20, Charles River Laboratories) by the 
inoculation of 1x106 HSC-2 cells into the dorsal flank. At 
7 days after tumor cell inoculation, the mice were divided 
into 4 groups (control, cetuximab-treated, TM-treated, and 
TM- and cetuximab-treated). The mice were treated with 
an intraperitoneal injection of 100 µl of solution containing 
cetuximab (1 mg/kg) in PBS or PBS alone twice a week for 
5 weeks. The mice were treated with orally adminisitration of 
100 µl of a solution containing TM (1 mg) or DDW, 5 times a 
week for 5 weeks. The tumor volume (cubic mm) was calcu-
lated using the following equation: 4π/3xr1/2xr2/22, where r1 
is the longitudinal diameter, and r2 is the transverse diameter. 
At 5 weeks after tumor cell inoculation, all the mice were then 
sacrificed, and the volume of tumors was measured.
All the animal experimental protocols were approved by 
the Ethics Review Committee for Animal Experimentation 
of the Okayama University Graduate School of Medicine 
and Dentistry with the following approval numbers: 
OKU-2016055 (for human oral squamous cell carcinoma 
xenografts), OKU2016060 (isolation of bone-related cells) and 
OKU-2016056 (inoculation of cancer cells into bone marrow).
Statistical analysis. The experiments were performed in 
quadruplicate. Data were analyzed using an unpaired Student's 
t-test for the analysis of two groups, and one-way ANOVA 
with Bonferroni and Dunnett's post hoc tests for the analysis 
of multiple group comparisons using SPSS statistical software. 
The results are expressed as the means ± SD. A value of P<0.05 
was considered to indicate a statistically significant difference.
Results
TM suppresses the growth of oral squamous cell carcinoma 
cells. To examine the antitumor effects of TM against oral 
squamous cell carcinoma in vitro, we performed a trypan 
blue staining assay. As shown in Fig. 1A-C, TM significantly 
reduced the number of viable HSC-2, HSC-3 and SAS cells 
proportionately with the increasing concentrations 5 days 
after treatment. In the same experiment, the concentrations of 
copper ion in the conditioned media of the HSC-2, HSC-3 and 
SAS cells treated with 5 µM TM for 72 h was decreased by 
approximately 30% (Fig. 1D). By contrast, TM did not affect 
the proliferation of fibroblasts, osteoblasts, osteocytes and 
T cells, which are components of the bone microenvironment 
(Fig. 1E-H).
To examine the antitumor effects of TM in vivo, we 
established an HNSCC xenograft tumor derived from HSC-2 
cells in nude mice. The mice were treated with TM (1 mg; 
5 times a week) and/or cetuximab (1 mg/kg; twice a week) 
for 5 weeks beginning at 7 days after tumor cell inoculation, 
and the tumor volume was measured at day 35. As shown in 
Fig. 2A, the HSC-2 xenograft tumor volumes were significantly 
Figure 2. Effects of TM and cetuximab on oral squamous cell carcinoma cells 
grown in mice. (A) Tumor growth is expressed as the mean tumor volume ± SD; 
*P<0.05 vs. control. (B) Immunohistochemical analysis of Ki67 in xenograft 
tumors. (C) The percentage of Ki67-positive cells in each section; *P<0.05 vs. 
control.
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decreased in the TM-or cetuximab-treated mice compared 
to the untreated mice. No significant toxicity was observed 
during the treatment period. At sacrifice after the treatment 
period with TM or cetuximab, the tumors were excised and 
examined histologically. Immunohistochemical analysis 
revealed a significant decrease in the number of Ki67-positive 
tumor cells in the HSC-2 tumor sections from the TM-treated 
and cetuximab-treated mice (Fig. 2B and C). TM treatment 
led to a positive trend by enhancing the antitumor effects of 
cetuximab (cetuximab single treatment vs. combined treat-
ment, P=0.057). TM or cetuximab did not cause any body 
weight loss at the end of experiment [mean body weight (g): 
control, 23.01; TM, 23.15; cetuximab, 24.15; and TM + cetuz-
imab, 22.8]. None of the animals experienced >20% decrease 
in body weight during the experiment. However, no statistically 
significant differences were observed between single treatment 
and combination treatment with TM and cetuximab as regards 
by tumor volume in this soft tissue tumor model. These results 
suggest that antitumor effects of TM require further evaluation 
in soft tissue HNSCC models in order to definitively evaluate 
its direct anticancer activity.
TM suppresses osteoclast formation. Copper ions are known to 
play a key role in bone remodeling (5); however, the effects of 
copper chelating on bone cancer remain unknown. To examine 
the effects of TM on osteoclast formation, we treated murine 
total bone marrow cells harvested from mouse tibias with 
vitamin D3 (1x10-8 M) in the presence or absence of TM for 
5 days. TM inhibited the number of TRAP-positive multinucle-
ated osteoclasts in a dose-dependent manner (Fig. 3A and B). 
Figure 3. Effect of ammonium tetrathiomolybdate (TM) on osteoclastogenesis. (A and B) Total bone marrow cells were cultured with TM (0, 0.1, 1, 2.5, or 
5 µM) in the presence of vitamin D3, 1,25-Dihydroxy (10-8 M) in a 24-well plate for 9 days. (B) The numbers of TRAP-positive multinucleated cells (nuclear 
number >3) were counted as osteoclasts (y-axis). Data are the means ± SD; *P<0.05 between the indicated groups. (C) Copper concentration in bone marrow 
cell cultured medium in the presence of vitamin D3, 1,25-Dihydroxy (10-8 M) with or without TM (0.1, 1, 5 µM) for 3 days. Data are means ± SD; *P<0.05 vs. 
control (D) RAKNL expression in bone marrow cell culture medium in the presence of vitamin D3, 1,25-Dihydroxy (10-8 M) with or without TM (0.1, 1, 5 µM) 
for 3 days. (E) CD11b-positive pre-osteoclasts were cultured with TM (0, 0.1, 1, 5 µM) in the presence of 30 ng/ml M-CSF and 50 ng/ml RANKL in a 24-well 
plate for 9 days. TRAP-positive multinucleated cells (nuclear number >3) were counted as osteoclasts. Data are the means ± SD.
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The copper concentration in the cell conditioned media and 
RANKL expression in bone marrow cells were decreased by 
TM treatment in a dose-dependent manner (Fig. 3C and D). 
By contrast, TM did not affect RANKL-induced osteoclast 
differentiation on CD11b-positive bone marrow cells (Fig. 3E). 
These results indicate that copper chelating by TM suppresses 
osteoclast formation via indirect osteoclast differentiation, 
such as that represented by RANKL expression in osteoblasts.
TM suppresses cancer cell-derived LOX activation via copper 
chelating. The enzyme activity of LOX was activated by 
copper binding to pro-LOX. Fig. 4A illustrates soluble LOX 
activation increased by copper ion (10 µM) from the condi-
tioned media of the cancer cells and bone microenvironment 
cells. Both the SAS and HSC-2 cells released a large amount of 
activated LOX compared to the bone microenvironment cells, 
i.e., the fibroblasts, osteoblasts and osteocytes. As expected, 
TM suppressed LOX activation in the conditioned medium of 
HNSCC cells via copper chelating (Fig. 4B and C).
TM suppresses RANKL expression in osteoblasts and osteo-
cytes in vitro. To examine the effects of copper-induced LOX 
activation on RANKL expression in bone marrow cells, we 
treated osteoblasts and osteocytes with HSC-2 conditioned 
medium and cultured the cells in increased copper ion concen-
trations with or without TM for 24 h. The HSC-2 conditioned 
medium and the presence of increased copper ions promoted 
RANKL expression in the osteoblasts and osteocytes. TM 
treatment decreased this effect via copper chelating (Fig. 4D).
TM decreases the copper levels and cancer-induced LOX 
activity in vivo. To build on these findings, we evaluated the 
effects of TM on bone destruction and resorption induced 
by the injection of HSC-2 cells into mouse tibiae. The results 
Figure 4. Effect of ammonium tetrathiomolybdate (TM) on LOX activity in cancer cells and the expression of RANKL in cells of the bone microenvironment. 
(A) LOX activation in conditioned media of HNSCC cells and bone microenvironmental cells. LOX activation is shown as the relative ratio. HSC-2 cells were 
used as a control (1.0). Data are the means ± SD; *P<0.05 vs. HSC-2 cells. (B) LOX activation in (B) SAS or (C) HSC-2 cell conditioned media with increased 
concentrations of copper ion (10 µM) with or without 5 µM TM. LOX activation is shown as the relative ratio. Medium was used as the control (1.0). Data 
are the means ± SD; *P<0.05 vs. medium, **P<0.05 vs. cancer CM, ***P<0.05 vs. Cu2+-added cancer CM (D) Osteoblasts and osteocytes were treated with the 
previously prepared HSC-2 conditioned medium for 24 h. RANKL expression in the osteoblasts and osteocytes was evaluated by western blot analysis.
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demonstrated that the serum copper levels were increased in 
the mice injected with the HSC-2 into the tibiae, and this was 
suppressed by treatment with TM (Fig. 5A).
As expected, HSC-2 cell inoculation into the tibiae 
increased LOX activity in bone marrow, and treatment with 
TM and cetuximab significantly decreased this activity 
(Fig. 5C). However, TM did not affect the whole serum LOX 
activity (Fig. 5B). These data thus demonstrated that TM and 
cetuximab suppressed the local LOX activation in bone by 
chelating copper ion.
Cetuximab reduced LOX activation in bone marrow 
in vivo (Fig. 5C). We also evaluated the effects cetuximab 
treatment on RANKL expression in osteoblasts and osteocytes 
in vitro. Surprisingly, conditioned medium from the HSC-2 
cells treated with cetuximab markedly decreased RANKL 
expression in osteoblasts and osteocytes (Fig. 5D). Cetuximab 
decreased the number of HNSCC cells in vitro and thereby 
cetuximab may suppress the amount of LOX in media.
TM enhances the anticancer effects of cetuximab and prevents 
bone resorption in vivo. We examined the in vivo effects of 
TM on osteolytic bone destruction induced by oral squamous 
carcinoma by conducting soft X-ray and micro-CT examina-
tions. As shown in Fig. 6A and B, the osteolytic lesions were 
clearly visible in the tibiae of mice with bone invasion induced 
by HSC-2 cells treated with the vehicle only. Surprisingly, 
few destructive lesions were detected in the tibiae of mice 
treated with TM. The total area of radiographic osteolytic 
Figure 5. Effect of ammonium tetrathiomolybdate (TM) on the copper levels and LOX activity in free blood serum from mouse models of HSC-2-induced 
cancer bone invasion. At 7 days after tumor inoculation into he tibial bone marrow, mice were orally administered TM (1 mg/body) or DDW 5 times a week for 
5 weeks. Mice were intraperitoneally administered cetuximab (1 mg/kg) or PBS twice a week for 5 weeks (n=5/group). Copper levels in free blood and LOX 
activation in whole blood serum and bone marrow serum were measured in mice injected with the HSC-2 cells into their tibiae following treatment with TM or 
cetuximab alone or in combination. (A) Copper levels in free blood serum of the mouse model of bone invasion. Data are the means ± SD; *P<0.05 vs. controls, 
**P<0.05 vs. HSC-2 tumor cell-injected mice. (B) Analysis of LOX activity in whole blood serum. (C) Analysis of LOX activity analysis in bone marrow serum. 
LOX activation is shown as the relative ratio. Data are the means ± SD; *P<0.05 vs. control, **P<0.05 vs. HSC-2 tumor cell-injected mice. (D) Osteoblasts and 
osteocytes were treated with the HSC-2 culture medium with increased concentrations of copper ion in the presence or absence of cetuximab for 24 h. RANKL 
expression in osteoblasts and osteocytes was evaluated by western blot analysis.
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lesions from all tibiae was significantly suppressed by TM 
treatment compared to the controls (P<0.05). Cetuximab is a 
standard of care agent for the treatment of human head and 
neck cancers (16), and it is well known to suppress HSC-2 cell 
growth. Surprisingly, TM enhanced the antitumor effects of 
cetuximab in bone (Figs. 6C and 7A). Treatment with both TM 
and cetuximab alone decreased cancer cell proliferation in 
bone marrow. Furthermore, combination treatment with TM 
and cetuximab intensively suppressed tumor cell proliferation 
in bone marrow compared to treatment with each agent alone.
In addition, the numbers of RANKL-positive cells and 
TRAP-positive osteoclasts were significantly decreased in the 
tibiae of the mice treated with both agents compared with the 
mice treated with single treatment (TM or cetuximab only) 
(P<0.05; Fig. 7B-D). To build on these findings, we examined 
the activity of cetuximab in this model. Cetuximab suppressed 
EGFR levels and phosphorylated EGFR expression in these 
bone marrow tumors. In addition, combined treatment with 
cetuximab and TM enhanced the suppressive effects on the 
epression of EGFR, phosphorylated EGFR, CD31 and Ki67 
compared with single treatment (Fig. 8A).
These results suggest the following: i) TM significantly 
suppresses oral squamous cell carcinoma via the suppres-
sion of osteoclastogenesis and angiogenesis in osteolytic 
bone destruction that is associated with the invasion of oral 
squamous cell carcinoma; and ii) TM may enhance the effec-
tiveness of cetuximab.
Discussion
Copper chelators have been previously reported to inhibit 
cancer cell growth in vitro and in vivo (7,16,17). LOXs are 
copper-dependent enzymes. Copper ion binding to pro-LOX 
is necessary for LOX activation (9,18). The most well-studied 
roles of LOX enzymes are in the remodeling of the ECM and 
angiogenesis. It has been reported that cancer-derived LOX 
induces bone destruction in HNSCC and other malignan-
cies (19-21); however, the role of copper ion involvement in 
bone destruction induced by HNSCC is not yet well under-
stood. To the best of our knowledge, the present findings are 
the first to demonstrate that the chelation of copper ions by 
TM, inhibited LOX activation from HSC-2 head and neck 
Figure 6. Effects of ammonium tetrathiomolybdate (TM) on mouse models of cancer-associated osteolysis. (A and B) Representative radiographs and 
micro-CT of tibia from mice with bone invasion following the injection of HSC-2 cells and treated with TM or cetuximab alone, or their combination (n=5/
group). (C) Osteolytic lesion area in tibia from mouse. The osteolytic area. Data are the means ± SD; *P<0.05 vs. HSC-2-injected mice; **P<0.05 vs. mice treated 
with cetuximab or TM alone.
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Figure 7. Histological and histomorphometric analysis of the bone marrow in the mouse model of bone invasion. The sections of previous-experiment mice 
tibial bone marrow were stained with (A) hematoxylin and eosin (H&E), (B and C) TRAP and (D) RANKL (n=5/group). The numbers of osteoclasts in bone 
marrow are presented as thee means ± SD; *P<0.05 vs. control, **P<0.05 vs. treatment with ammonium tetrathiomolybdate (TM) or cetuximab alone.
Figure 8. Immunohistological analysis of the bone marrow in the mouse model of bone invasion. Representative sections of mice tibial bone marrow stained 
with (A) EGFR, (B) p-EGFR, (C) CD31 and (D) Ki67 (n=5/group).
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cancer cell models. In an earlier study, LOX was shown to 
increase RANKL expression in osteoblasts and consequently 
promote osteoclastogenesis (11). In this study, we observed 
that copper chelation by TM inhibited RANKL expression in 
osteoblasts and osteocytes via LOX suppression, resulting in 
an inhibition of the bone destruction associated with HNSCC 
invasion. These results indicate that copper ions are a critical 
mediator of osteolytic bone destruction in the bone tumor 
microenvironment.
Our experiments revealed that the oral squamous cell 
carcinoma HSC-2 and SAS cells were potently and effectively 
inhibited by TM at the level of proliferation. TM inhibited 
HSC-2 and SAS cell growth at an IC50 of 1-5 µM, whereas 
TM did not inhibit the growth of the fibroblasts, osteocytes, 
osteoblasts or T cells at the IC50 of 5 µM (Fig. 1D-G), which 
is consistent with previous findings (22). The discrepancy in 
IC50 results may be due to differences in the cellular systems, 
and cancer cells may be more sensitive to copper metabolism 
than normal cells. We also observed that the administration of 
TM exhibited efficacy in the HSC-2 xenograft model, where 
TM inhibited tumor growth in vivo. Furthermore, TM demon-
strated a positive trend by enhancing the antitumor effects of 
cetuximab, which is an EGFR receptor inhibitor used to treat 
head and neck cancer patients (cetuximab single treatment 
vs. combined treatment, P=0.057). However, there no statis-
tically significant differences were observed between single 
treatment and combined treatment with TM and cetuximab as 
regards tumor volume in this soft tissue tumor model. These 
results suggest that the antitumor effects of TM require further 
evaluation in soft tissue HNSCC tumor models in vivo.
In our investigation of the molecular mechanisms of 
action of TM in osteoclastogenesis in total bone marrow cells 
and CD11b-positive bone marrow cells, the data indicated 
that TM inhibited osteoclastogenesis from total bone marrow 
cells induced by vitamin D3 (Fig. 3A and B). However, TM did 
not affect RANKL-induced osteoclast differentiation from 
CD11b-positive cells (Fig. 3E). These data indicated that TM 
did not have a direct effect on osteoclast precursor cells, but 
did have an effect on other cells of the bone microenviron-
ment.
TM reduced LOX activation in the HSC-2 and SAS 
cells following copper ion treatment. It has been previously 
reported that LOX induces RANKL expression in osteo-
blasts (11). Consistently, the present findings demonstrated that 
the suppression of LOX downregulated RANKL expression 
in osteoblasts and osteocytes, resulting in the suppression 
of the differentiation of osteoclasts. The HSC-2 and SAS 
head and neck cancer cells released significant amounts of 
LOX (Fig. 4A). Copper ions increased LOX activation and 
TM suppressed it. These data indicated that TM may have a 
potent antitumor effect in bone-invasive HNSCC cells by not 
only suppressing tumor growth, but also by suppressing bone 
resorption by osteoclasts. To test this hypothesis, we created an 
HNSCC bone destruction mouse model, and treated the mice 
with TM. As expected, the serum copper levels in the mice 
injected with HSC-2 cells in their tibiae that were treated with 
TM were decreased compared to those of the untreated mice. 
The intratibial LOX activation in these mice was decreased 
similar to the serum copper levels. By contrast, there were 
no differences in LOX activation in blood serum. These data 
indicated that pro-LOX from cancer cells and copper ions are 
necessary for LOX activation and bone destruction.
Studies have reported that copper and LOX promote 
EGFR activation (22,23). In the present study, TM inhibited 
EGFR and phosphorylated EGFR expression in HSC-2 tumors 
in vivo. This mechanism may result in reduced Ki67 expression 
and consequent tumor growth suppression. To test the effects 
of TM in vivo, we treated the mice in the bone-destructive 
HNSCC model with TM, cetuximab or both, and the results 
indicated that single treatment with TM and single treatment 
with cetuximab reduced tumor growth in the bone (Fig. 6), 
and the combination treatment significantly decreased tumor 
growth and bone resorption compared to single treatment with 
either agent alone. This additive effect was due to the suppres-
sion of osteoclast formation, angiogenic potential and EGFR 
activity (Figs. 7B-D, and 8A-C).
In conclusion, copper may be a target for the treatment of 
bone osteolysis induced by HNSCC, and our findings strongly 
suggest that the single use of TM or combination treatment 
with TM and approved agents, such as cetuximab requires 
further evaluation as a potential novel therapy for the treat-
ment of advanced bone invasive HNSCC.
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